Ardelyx Shares Surge on Promising Clinical Trial Results
Investors are showing renewed confidence in Ardelyx following the release of compelling new clinical data for its treatment IBSRELA.
The pharmaceutical company presented these findings at the recent ACG congress, revealing that 88% of patients expressed satisfaction with their treatment regimen. Even more impressively, 95% of participants reported significant improvement in their constipation symptoms.
Significant Symptom Improvement Documented
A detailed post-hoc analysis demonstrated substantial therapeutic benefits across multiple symptom areas.
- Among IBS-C patients, 75% experienced reduced bloating
- 84% noted improved abdominal pain relief
- Over 70% of clinical trial subjects regained their ability to perform daily activities without restriction
No specific quote available.
Author's summary: Ardelyx shares rise after promising IBSRELA trial results.
More News
- BBMF's Avro Lancaster Begins Major Maintenance Overhaul
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- A pyrrhic budget victory could land Carney in the legislative hurt…
- Baxter stock slides as Q3 sales come up short, guidance lowered
- Why Israel Lost the Gaza Opinion War
- Integra stock dips on lowered guidance after Q3 sales miss
- I didn’t miss the irony of Invisible Disabilities Week going unnoticed
- Eala falls to Mboko to exit Hong Kong Open
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Best early Black Friday deals 2025: 40+ sales out early